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HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN
PHARMACEUTICAL CARE: EVALUATING PHARMACIST’S
KNOWLEDGE, UNDERSTANDING AND PERCEIVED BARRIERS
IN PHARMACY PRACTICE
Chandak P1,Wu WK2, Pantaleo N3
1St. John’s University, Queens, NY, USA, 2St. John’s Univesity, Queens,
NY, USA, 3Jamaica Hospital Medical Center, Jamaica, NY, USA
OBJECTIVES: Considerable evidence of the positive impact of
pharmaceutical care services on patient’s HRQoL outcomes has
been reported. However, the implementation of HRQoL assess-
ment in routine pharmaceutical care has been limited. This study
aimed to assess the relevance of and challenges in the applica-
tion of HRQoL evaluation in the provision of pharmaceutical
care. METHODS: A self-administered survey of pharmacist was
conducted during a regional continuing education program in
New York metropolitan area. 83 pharmacists working mainly in
community setting participated in the study. RESULTS: Major-
ity of the respondents were male (81.9%), with extended (>16
years) practice experience (65.1%). More than 78.3% of respon-
dents indicated that HRQoL measures could be a useful tool to
assess patient’s health status. 55% of the respondents agreed that
positive results of HRQoL evaluations could help in obtaining
reimbursement for pharmaceutical care services. However, about
70% reported no familiarity with instruments such as SF-36/12,
EuroQOL, or FACT. Respondents rated clinical activities such
as patient outcomes evaluation and designing a therapeutic mon-
itoring plan as less important in the provision of pharmaceuti-
cal care compared to conventional activities (p < 0.05). Those
who reported better understanding about pharmaceutical care
tend to report greater knowledge regarding HRQoL outcomes
assessment. (p < 0.05) More than half reported difﬁculty in
choosing appropriate HRQoL instruments (56.6%) and chal-
lenges in interpreting HRQoL results (54.5%) as major barriers.
About 84.6% of the respondents indicated willingness to learn
more about HRQoL assessment to address such issues. CON-
CLUSIONS: Study respondents recognized the positive implica-
tions of HRQoL evaluations in practice. Incorporating HRQoL
measures in practice could facilitate better understanding of the
focus of pharmaceutical care among practitioners. However,
further training and education is required by a pharmacist to
implement HRQoL evaluation. Further research to include the
perception of pharmacists from different practice settings and
recent PharmD graduates is warranted.
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DEVELOPING A MEASURE OF PATIENT EMPOWERMENT TO
BE APPLIED IN THE GENERAL COMMUNITY
Loukanova S, Bridges JFP
University of Heidelberg, Heidelberg, Germany
Patient empowerment has become a hot topic in academic med-
icine in recent years, however, most measures of empowerment
are disease speciﬁc, and often focus a particular issue such as
communication. There is a real need to develop measure of
patient empowerment that is both holistic and can be applied to
a general population. OBJECTIVES: To identify a holistic and
grounded conceptual model of empowerment that can serve as
a foundation for the development of a scale to measure patient
empowerment in the general community. METHODS: An exten-
sive literature review was used to review all MEDLINE articles
on empowerment over the past 20 years in order to: 1) deﬁne
what patient empowerment is and how it has been used in liter-
ature, and 2) what factors deﬁne patient empowerment. Based
on the results of this review, a draft conceptual model was devel-
oped and validated by a purposively selected group of experts
selected from a range of professional backgrounds in medicine.
RESULTS: In total 20 experts from 6 different countries 
participated, who suggested a range of improvements on the 
conceptual model. They also suggested a number of methods to
both measure preference and identify if patient, in fact, had a
preference for being empowered. Our study found that patient
empowerment can be measured over eight domains, categorized
into two main groups: human capital (knowledge; health 
status/outcomes; literacy; and ownership and responsibility) 
and health care system resources (access; advocacy; joint deci-
sion making and capacity and willingness to engage patients).
CONCLUSIONS: This paper demonstrates that patient empow-
erment is indeed multi-faceted. Future research will focus on
developing a scale to measure patient empowerment and to
determine whether patients have preferences to be empowered.
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CLUSTER ANALYSIS OF STATE MEDICAID PROGRAMS
Roy S, Madhavan SS
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Policy makers and Medicaid administrators often
attempt to replicate cost containment strategies that have
worked in apparently similar states. Such measures result in
varied degrees of success owing possibly to not-so-obvious dif-
ferences between the states’ characteristics and determinants of
prescription drug expenditure. This study attempts to identify
homogenous groups (or clusters) of state Medicaid programs
based on variables that describe such characteristics, drug expen-
ditures and their determinants. METHODS: Variables were iden-
tiﬁed following Andersen’s Behavioral Model for Health Services
Utilization. Latest available data (2002) were obtained for the
above variables from public data sources for 48 fee-for-service
state Medicaid programs. Hierarchical Cluster Analysis tech-
nique was employed to identify optimum number of homoge-
neous groups of states by minimizing within-group variation and
maximizing between-group variation. Optimum number of 
clusters was identiﬁed based on the values of the R-squared
(RSQ), cubic clustering criterion (CCC), and pseudo F (PSF) sta-
tistics. Following identiﬁcation of optimum number of clusters,
cluster memberships were assigned and variables that deﬁned
cluster characteristics were identiﬁed. RESULTS: The ﬁrst step
identiﬁed seven clusters to appropriately classify the 48 state
Medicaid programs; RSQ = 68.6%, CCC = 2.0, and PSF = 14.9.
The second step assigned cluster memberships ranging from 2 
to 15 member states in a cluster. Key variables which described
the differences in cluster characteristics were: poverty levels 
(p = 0.024), access to primary care (p = 0.000), access to 
hospitals (p = 0.025), Federal matching for state drug expendi-
ture (p = 0.044), budgetary support for healthcare (p = 0.000),
drug expenditures (p = 0.043), and medical services expenditures
(p = 0.000). CONCLUSIONS: Identiﬁed clusters and their 
membership were not restricted to the commonly considered 
criteria of geographic proximity, socioeconomic characteristics,
or program expenditure levels. Hence, knowledge of these
groups, their membership, and the key variables that character-
ize them can further inform decision-making resulting in 
implementation of more cost-effective policy measures for 
Medicaid.
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OBJECTIVE: Determine whether physicians spend more time
with patients prescribed high-risk medications—-anticoagulants,
anticonvulsants, antiarrythmics, antidiabetics and beta ago-
nists—-that require either additional patient education about
correct use and adverse effects or increased monitoring by
providers. METHODS: Patient visit data to physicians from the
2003 National Ambulatory Medical Care Survey (n = 17,078)
were used in multiple regression (SPSS 12.0, á = 0.05). Visit time
was the dependent variable. Independent variables included indi-
cator variables for prescribing each high-risk medication and
visit circumstances hypothesized to require more time—1)
patient was new to the practice; 2); patient’s condition was new;
and 3) physician was not the patient’s primary physician. Inter-
actions between high risk medication prescribing and visit cir-
cumstances were also examined. Control variables included
modiﬁed Charlson index, diagnostic and counseling services pro-
vided, patient and provider demographics. RESULTS: Visits
lasted an average of 19 minutes. Signiﬁcantly higher visit times
were found for patients prescribed either anticonvulsants, anti-
coagulants or antidiabetics. Visit times were additionally higher
if 1) the condition was new and the patient was prescribed anti-
convulsants or antidiabetics, or 2) the patient was new to the
practice and was prescribed anticonvulsants. Patients not seeing
their primary physician had lower visit times if they were pre-
scribed anticoagulants or antidiabetics. No visit time increases
were associated with antiarrythmics or beta agonists. CON-
CLUSION: Visit times increased with the prescribing of certain
high-risk medications in our study and during certain visit cir-
cumstances. However, increases were not uniformly found across
all high-risk medications examined. This gap in care suggests
that less expensive healthcare providers like pharmacists are
needed to enter into collaborative working relationships with
physicians to provide counseling, education and monitoring for
these medications.
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INFECTION—Clinical Outcomes Studies
PIN1
HEPATOTOXICITY ASSOCIATED WITH RIFAMPIN AND
PYRAZINAMIDE THERAPY OF LATENT TUBERCULOSIS
INFECTION:A META-ANALYSIS
Ghosh S
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: Observational studies individually don’t shed
much light on the association of hepatotoxicity with rifampin
and pyrazinamide (RPZ) therapy .The following a priori
hypotheses were tested : 1) Every study will have an effect size
greater than one; 2) Effect size will vary depending on head count
for various risk factors; 3) Intensive monitoring of RPZ therapy
reduce hepatotoxicity. In addition to research hypotheses the fol-
lowing research questions were identiﬁed: 1) Who are at greater
risk of having hepatotoxicity; 2) Is alcohol an effect modiﬁer or
a confounder? METHODS: For this research only the observa-
tional studies were selected. Electronic searches of MEDLINE
(1980 to Aug 2005) were carried out to identify relevant papers.
An instrument was devised to assess the quality of the selected
studies which measures the quality of the study in range of
1–10.Consistency of the items included in the instrument was
described by Cronbach’s á (0.7). Review Manager 4.2 (Cochrane
Collaboration Center) used to do the meta-analysis. Regression
analysis was performed to ﬁnd relationship between effect size
and certain risk factors. RESULTS: The odd ratio of the pooled
data is 2.98(2.16–4.11). One of the studies has an effect size of
0.71(0.22–2.27). The odd ratio for risk factors are: liver disease-
5.14(1.64–16.10); race-1.85(0.88–3.91); gender-1.66(0.87–
3.15); alcohol-1.51(0.82–2.75); age-1.15(0.51–2.62). The odd
ratios across the alcoholics and non alcoholics strata are equal.
The odd ratio of hepatotoxicity is 0.54(0.21–1.37) among
patients who underwent intensive monitoring of RPZ therapy.
The R square of the regression for the relationship between effect
size, female and non blacks is 0.94. CONCLUSIONS: The meta-
analysis of data shows that RPZ users are at higher odd of having
hepatotoxicity. The effect size is related to number of female and
non black patients included. Female, older, black, and alcoholic
are at higher risk. Alcohol is a confounder. Monitoring does
reduce the cases of hepatotoxicity.
INFECTION—Cost Studies
PIN2
COST COMPARISON OF A ONCE-DAILY PARENTERAL
ANTIBIOTIC IN HOSPITAL SETTINGS: INFORMATION FROM
THE SIDESTEP STUDY
Turpin RS1,Tice A2,Wu JH1,Taylor S1, Polis A1,Abramson M1
1Merck & Co., Inc, West Point, PA, USA, 2University of Hawaii,
Honolulu, HI, USA
OBJECTIVES: Diabetic foot infections (DFI) account for more
hospital days than any diabetes-related diagnosis. Many patients
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